Evidence map›Paper›PMID 22654108›Full record

ArticleThe Journal of biological chemistry2012

A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression.

Loukia G Karacosta, Barbara A Foster, Gissou Azabdaftari, David M Feliciano, Arthur M Edelman

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. The role of CaMKK2 in Golgi-associated vesicle trafficking.Biochemical Society transactions · 2023
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Loukia G KaracostaDepartment of Pharmacology and Toxicology, State University of New York, Buffalo, New York 14214, USA.
Barbara A Foster
Gissou Azabdaftari
David M Feliciano
Arthur M Edelman
Roswell Park Comprehensive Cancer Center · USUniversity at Buffalo, State University of New York · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Vitamin D Analogs for Chemoprevention of Prostate CAncerR01CA095367 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI FOSTER, BARBARA A. · 2002 to 2012
$3.2M
Identification of In Vivo Targets of Protein KinasesR21NS050385 · NINDS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI EDELMAN, ARTHUR M · 2004 to 2005
$382k
NCI NIH HHS CA016056NCI NIH HHS CA095367NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA095367NINDS NIH HHS NS50385NINDS NIH HHS R21 NS050385
6 · The paper itself

Abstract

The androgen receptor (AR) plays a critical role in prostate cancer (PCa) progression, however, the molecular mechanisms by which the AR regulates cell proliferation in androgen-dependent and castration-resistant PCa are incompletely understood. We report that Ca(2+)/calmodulin-dependent kinase kinase 2 (CaMKK2) expression increases and becomes nuclear or perinuclear in advanced PCa. In the TRAMP (transgenic adenocarcinoma of mouse prostate) model of PCa, CaMKK2 expression increases with PCa progression with many cells exhibiting nuclear staining. CaMKK2 expression is higher in human castration-resistant tumor xenografts compared with androgen-responsive xenografts and is markedly higher in the AR-expressing, tumorigenic cell line LNCaP compared with cell lines that are AR-nonexpressing and/or nontumorigenic. In LNCaP cells, dihydrotestosterone induced CaMKK2 mRNA and protein expression and translocation of CaMKK2 to the nucleus. Conversely, androgen withdrawal suppressed CaMKK2 expression. Knockdown of CaMKK2 expression by RNAi reduced LNCaP cell proliferation and increased percentages of cells in G(1) phase, whereas correspondingly reducing percentages in S phase, of the cell cycle. CaMKK2 knockdown reduced expression of the AR target gene prostate-specific antigen at both mRNA and protein levels, AR transcriptional activity driven by androgen responsive elements from the prostate-specific probasin gene promoter and levels of the AR-regulated cell cycle proteins, cyclin D1 and hyperphosphorylated Rb. Our results suggest that in PCa progression, CaMKK2 and the AR are in a feedback loop in which CaMKK2 is induced by the AR to maintain AR activity, AR-dependent cell cycle control, and continued cell proliferation.

Indexed as

AnimalsBlotting, WesternCalcium-Calmodulin-Dependent Protein Kinase KinaseCell CycleCell Line, TumorCell ProliferationCell SurvivalHumansImmunohistochemistryIn Vitro TechniquesMaleMiceProstatic NeoplasmsReceptors, AndrogenReverse Transcriptase Polymerase Chain ReactionRNA InterferenceCalcium-Calmodulin-Dependent Protein Kinase KinaseCAMKK2 protein, humanCamkk2 protein, mouseReceptors, Androgen

Identifiers

PMID22654108
PMCPMC3397910
OpenAlexW2052612645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.